ivolumab plus Ipilimumab versus existing immunotherapies in patients with PD-L1-positive advanced non-small cell lung cancer: a systematic review and network meta-analysis.
Not Applicable
- Conditions
- PD-L1-positive previously untreated advanced non-small cell lung cancer
- Registration Number
- JPRN-UMIN000039784
- Lead Sponsor
- Showa University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 4011
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with EGFR-sensitive mutations wereexcluded in the case of histologically squamous cell carcinoma.
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method